Mometasone
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Mometasone: From Topical Corticosteroid Therapy to Primary Cutaneous T-Cell Lymphoma
One-Sentence Summary
Mometasone is a corticosteroid; its specific original indication is not detailed in the current evidence pack (regulatory license data unavailable). The TxGNN model predicts potential effectiveness for Primary Cutaneous T-Cell Lymphoma, but this direction is currently supported only by 0 clinical trials and 2 case-report-level publications, neither of which directly evaluates mometasone in this disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (no license/indication records) |
| Predicted New Indication | Primary Cutaneous T-Cell Lymphoma |
| TxGNN Prediction Score | 99.36% |
| Evidence Level | L5 |
| Germany Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known pharmacology, mometasone is a topical corticosteroid; its efficacy relies on general anti-inflammatory and immunosuppressive activity rather than a disease-specific target.
The repurposing rationale here is mechanistic, not evidentiary: topical corticosteroids are listed in some clinical guidelines (e.g., NCCN) as a skin-directed supportive option for early-stage cutaneous T-cell lymphoma/mycosis fungoides, based on their general anti-inflammatory effect and ability to induce T-cell apoptosis. However, this biological plausibility is not confirmed by the literature actually retrieved for this candidate — one publication concerns a different drug (tapinarof, not mometasone) treating a different, non-malignant condition (cutaneous pseudolymphoma), and the other is a pediatric mycosis fungoides case report that does not evaluate mometasone as treatment at all.
In short, the prediction rests on class-level plausibility (corticosteroids as supportive skin-directed therapy in CTCL) rather than on direct clinical or trial evidence for mometasone in this indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40821495 | 2025 | Case Report | Proceedings (Baylor University Medical Center) | Cutaneous pseudolymphoma (not true CTCL) unresponsive to mometasone and tacrolimus; drug used but for a mimicking, non-malignant condition |
| 25442255 | 2015 | Case Report | Journal of Cutaneous Pathology | Pediatric CD8+CD56+ mycosis fungoides case describing immunophenotype; does not evaluate mometasone treatment |
Germany Market Information
Currently no marketing authorization records available (market status: not marketed; 0 licenses on file).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to model prediction (L5) with no clinical trials and only two case reports, neither of which provides direct evidence of mometasone use in primary cutaneous T-cell lymphoma. The mechanistic argument (corticosteroids as skin-directed supportive therapy in CTCL guidelines) is plausible but unconfirmed by the retrieved literature.
To proceed, the following is needed:
- Original indication and approved-label data for mometasone (currently missing — DG001)
- Detailed mechanism of action data from DrugBank (currently missing — DG002)
- TFDA/German (BfArM) label warnings and contraindications for S1 safety screening
- Literature or trial evidence directly evaluating mometasone (not other corticosteroids/agents) in confirmed CTCL/mycosis fungoides patients
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.